Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 59, Issue 1, 2008, Pages 69-75

  Han, Ji Youn ^a   Lim, Hyeong Seok ^a   Shin, Eun Soon ^b   Yoo, Yeon Kyeong ^b   Park, Yong Hoon ^a   Lee, Jong Eun ^b   Kim, Heung Tae ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Irinotecan; NSCLC; OATP1B1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INCIDENCE; KOREA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OATP1B1 GENE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 37549028363     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.07.019     Document Type: Article

References (21)

1. Ho R.H., and Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78 (2005) 260-277
2. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234 (2006) 4-33
3. Ito K., Suzuki H., Horie T., and Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22 (2005) 1559-1577
4. Nozawa T., Minami H., Sugiura S., Tsuji A., and Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33 (2005) 434-439
5. Kivisto K.T., and Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 24 (2007) 239-247
6. Niemi M., Schaeffeler E., Lang T., Fromm M.F., Neuvonen M., Kyrklund C., et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion-transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14 (2004) 429-440
7. Chung J.Y., Cho J.Y., Yu K.S., Kim J.R., Oh D.S., Jung H.R., et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78 (2005) 342-350
8. Pasanen M.K., Backman J.T., Neuvonen P.J., and Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 (SLCO1B1) gene in a Finnish population. Eur J Clin Pharmacol 62 (2006) 409-415
9. Niemi M., Neuvonen P.J., Hofmann U., Backman J.T., Schwab M., Lutjohann D., et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 15 (2005) 303-309
10. Han J.Y., Lim H.S., Lee D.H., Ju S.Y., Lee S.Y., Kim H.Y., et al. Randomized phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer 106 (2006) 873-880
11. Xiang X., Jada S.R., Li H.H., Fan L., Tham L.S., Wong C.I., et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 16 (2006) 683-691
12. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73 (2003) 554-565
13. O'Dwyer P.J., and Catalano R.B. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24 (2006) 4534-4538
14. Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2 (2002) 43-47
15. Innocenti F., Undevia S.D., Iyer L., Chen P.X., Das S., Kocherginsky M., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 (2004) 1382-1388
16. Premawardhena A., Fisher C.A., Liu Y.T., Verma I.C., de Silva S., Arambepola M., et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT 1A1): Hematologic and evolutionary implications. Blood Cells Mol Dis 31 (2003) 98-101
17. Han J.Y., Lim H.S., Shin E.S., Yoo Y.K., Park Y.H., Lee J.E., et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24 (2006) 2237-2244
18. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120 (2001) 525-533
19. Konig J., Cui Y., Nies A.T., and Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275 (2000) 23161-23168
20. Innocenti F., Undevia S.D., Rosner G.L., Xiao L., Liu W., Chen P., et al. Irinotecan pharmacokinetics and neutropenia: interaction among UGT1A1 and transporter genes. Proc Am Soc Clin Oncol 23 (2005) 2006
21. Niemi M., Backman J.T., Kajosaari L.I., Leathart J.B., Neuvonen M., Daly A.K., et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 77 (2005) 468-478